Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study

Table 1 Patient characteristics

#	Age	Sex	BMI (kg/m²)^a	Comorbidity	ESBL-Producer	ESBL-neg.^b after 1st FMT^c	ESBL-neg. after 2nd FMT	Donor FMT 1	Donor FMT 2
1	58	M	19	ESRD^d, PD^e, CVD^f	E. coli ^g	Y	–	1	–
2	47	M	27	Tetraplegia, rUTI^h	E. coli	N	–	1	–
3	65	M	25	Renal Tx^j, rUTI	E. coli	N	N	1	1
4	61	M	24	rUTI	K. p ^j	N	–	1	–
5	29	F	35	rUTI	E. coli	N	Y	1	2
6	56	F	28	RUTI	E. coli	N	N	1	2
7	70	F	28	Renal Tx, rUTI	K. p, E. coli	N	N	1	2
8	59	F	20	Renal Tx, rUTI, HBV^k	E. coli	Y	–	1	–
9	61	F	28	rUTI	E. coli	N	Y	1	1
10	57	F	26	ESRD, rUTI	E. coli	N	–	2	–
11	76	F	23	rUTI	E. coli	Y	–	2	–
12	70	M	24	Renal Tx, rUTI, T2D^l	E. coli	N	–	1	–
13	59	F	29	Renal Tx	K. p	N	N	1	1
14	58	F	36	rUTI	E. coli	N	Y	1	2
15	21	F	24	rUTI	E. coli	N	–	1	–

^aBody mass index, ^b extended-spectrum beta lactamase producer-negative, ^c fecal microbiota transplantation, ^d end-stage renal disease, ^e peritoneal dialysis, ^f cardiovascular disease, ^g Escherichia coli, ^h recurring urinary tract infections, ⁱ transplant, ^j Klebsiella pneumoniae, ^k Hepatitis B virus, ^l type 2 diabetes. Patient 7 had (only) K. pneumoniae before the 1st FMT and (only) E. coli before the second FMT

ISSN: 1756-0500